Piper Sandler on Verona Pharma (VRNA): 'We Remain Highly Bullish and See Substantial Upside'
Tweet Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $76.00 price target on Verona Pharma (NASDAQ: VRNA).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
